Stephen J. Freedland, MD

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

The series concludes with a forward-looking discussion on ongoing research and unresolved questions about long-term enzalutamide therapy. Freedland reflects on evolving treatment paradigms and offers key takeaways for practicing urologists to help guide their management of men with high-risk, biochemically recurrent prostate cancer.

Mechanisms of Action and Differentiation Among ARPI Therapies in mCSPC

Current Treatment Landscape and Guideline Recommendations in mCSPC

This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and disease-specific factors that drive the choice of androgen receptor inhibitor in clinical practice.

Freedland reviews enzalutamide’s long-term safety profile, drawing from the EMBARK, ARCHES, and ENZAMET trials. He explains strategies for managing adverse events, balancing efficacy with tolerability, and comparing safety outcomes across other androgen receptor pathway inhibitors to help clinicians personalize care.

This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these findings, how they may alter treatment guidelines, and the importance of counseling asymptomatic patients about the benefits of early systemic therapy.

Freedland explores how enzalutamide’s role has expanded from advanced settings to earlier use in high-risk, biochemically recurrent prostate cancer. He discusses the clinical rationale for early initiation, particularly for urologists less familiar with systemic therapy, and compares enzalutamide with other androgen receptor pathway inhibitors in this population.

Stephen J. Freedland, MD, shares 'unprecedented' overall survival data from the phase 3 EMBARK trial.

Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care.

Among men without prostate cancer at baseline, healthier dietary patterns appeared somewhat protective.

Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.

Investigators found that benefits of treatments that are observed in trials also appear in the real world.

"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.

Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.

Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.

Experts on prostate cancer discuss the relationship between prostate cancer and cardiovascular disease, highlighting ongoing research for safer treatment.

Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.

The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.

Experts on prostate cancer discuss factors to consider while making treatment decisions for patients with nonmetastatic castration-sensitive prostate cancer.

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.

Lawrence Karsh, MD, FACS, introduces a discussion on prostate cancer and androgen deprivation therapy with an overview of how the treatment landscape has changed in recent years.

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.

Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.